FSD BIO LABS · Product artwork
Studied for melanocortin signalling and sexual desire responses.
20 vials available
Full prepaid by UPI includes free delivery. COD requires 5% advance and a 1.5% delivery fee. Payment details
See delivery information and return conditions before ordering. Your final total is shown at checkout.
1 laboratory report available
Not for human or veterinary administration. Listed strength is a supplied specification; see the matching batch report for measured results.
1 report is available for this strength. Match the reported sample and available batch identifiers; contact support if the link to your vial is unclear.
View COA libraryPT-141, also known as bremelanotide, is a melanocortin receptor agonist. Clinical research on bremelanotide formulations has investigated sexual desire in women with hypoactive sexual desire disorder.
Each source identifies what was studied and the limits of its findings. Published research is separate from this product’s batch COA.
Two randomised trials examined a specific bremelanotide formulation in premenopausal women with diagnosed hypoactive sexual desire disorder. The research vial is not equivalent to that clinical formulation.
Read sourceThis analysis examined clinically meaningful questionnaire responses in premenopausal women with diagnosed sexual dysfunction. It is an analysis of one trial, not an independent trial or validation of a research vial.
Read sourcePT-141 is currently listed in 10 mg. Select a strength above to see its price, product image and current stock. Listed quantities are supplied specifications, not measured batch results.
1 laboratory report is published for this compound. Match the selected strength and available batch identifiers, and open the original document to check the actual test scope.
The references discuss the material and experimental conditions in those studies. They do not verify the identity, purity, quantity or suitability of this catalogue vial. Review the study limitations and the available batch documentation separately.
A CJC and ipamorelin blend intended for growth hormone signalling research.
Studied for growth hormone signalling and changes in visceral abdominal fat.
Studied for growth hormone release and growth hormone secretagogue signalling.
Studied for GHRH signalling and growth hormone/IGF-1 responses.